Transabdominal ultrasound (US) is the first-line imaging method used to diagnose pancreatic lesions, but contrast techniques are needed to differentiate among inflammatory and malignant lesions, as well as between pseudocysts and cystic tumors. Contrast-enhanced (CE) ultrasonography has been proven to be a useful tool in this regard with performance similar to contrast-enhanced computer tomography/magnetic resonance imaging (CT/MRI), being also safer and nonirradiant. According to the EFSUMB guidelines on the nonhepatic use of contrast-enhanced ultrasound (CEUS), this method is useful to improve characterization of ductal adenocarcinoma; to differentiate between pseudocysts and cystic tumors; to differentiate vascular (solid) from avascular (liquid/necrotic) components of a lesion; to better define the dimensions and margins of a lesion, including its relationship with adjacent vessels; and to help the choice for a next imaging technique.